Press Releases

Preterm infants must establish regular breathing patterns at delivery. For extremely preterm infants requiring resuscitation at birth, a ventilation strategy involving two sustained inflations, compared with standard intermittent positive pressure ventilation, did not reduce the risk of bronchopulmonary dysplasia (BPD) or death at 36 weeks’ postmenstrual age.

Despite an FDA approval of growth hormone treatment for children with idiopathic short stature (ISS), the mean cost burden to patients and their families has increased over time, according to findings from researchers at Children’s Hospital of Philadelphia (CHOP) and the Leonard Davis Institute of Health Economics (LDI) of the University of Pennsylvania.

Scientists have harnessed powerful data analysis tools and three-dimensional studies of genomic geography to implicate new risk genes for osteoporosis, the chronic bone-weakening condition that affects millions of people. Knowing the causative genes may later open the door to more effective treatments.

Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells.

For more than two decades, mutations in a gene located in the DNA of mitochondria have been classified as a mitochondrial disease and linked to a particular set of symptoms. However, according to new findings from researchers at Children's Hospital of Philadelphia (CHOP), mutations in this gene, which encodes an essential part of the mitochondrial motor known as ATP synthase that generates cellular energy, are much more variable than previously thought.

Automated programs can identify which sick infants in a neonatal intensive care unit (NICU) have sepsis hours before clinicians recognize the life-threatening condition. A team of data researchers and physician-scientists tested machine-learning models in a NICU population, drawing only on routinely collected data available in electronic health records (EHRs).

New preclinical findings from extensive cell and animal studies suggest that a drug already used for a rare kidney disease could benefit patients with some mitochondrial disorders—complex conditions with severe energy deficiency for which no proven effective treatments exist. Future clinical research is needed to explore whether the drug, cysteamine bitartrate, will meaningfully benefit patients.

A leading physician-researcher at Children’s Hospital of Philadelphia (CHOP) has received an award from the QED Program of the University City Science Center to help develop an innovative T-cell based treatment for the childhood cancer neuroblastoma.

As the opioid epidemic continues to plague the United States, physician researchers at Children’s Hospital of Philadelphia (CHOP) analyzed prescription patterns in children.

CHOP Researchers Report on the Delaney Twins One Year after Surgery